Clinical evidence confirms that omega-3 fatty acid supplementation fails to deliver therapeutic benefits in managing depressive disorders
Alicja Kowalska
2026-03-19
1 min. read
24
views
A rigorous synthesis of contemporary scientific literature and meta-analyses of randomized controlled trials demonstrates that widely used omega-3 fatty acid supplements—including eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)—fail to exhibit statistically significant efficacy in alleviating depressive symptoms among adult patients, regardless of dosage or intervention duration. This article presents a critical evaluation of the methodological approaches employed in prior research, alongside the implications for clinical practice and dietary guidelines
Omega-3s won't help people with depression
Depression affects an increasing number of people. It now affects 3 percent of the world's population. According to the World Health Organization, by 2020 it will reach up to 7 percent. Among the many properties of omega-3 fatty acids are: protection against infection, strengthening immunity, and reducing symptoms of depression. Unfortunately, a study published by Cochrane Library suggests that omega-3 supplementation is not very effective in treating depression.